AZD7442

AZD7442 is a Long Acting AntBody (LAAB) developed by AstraZeneca. Scientists from the University College London Hospitals NHS Trust (UCLH) believe that AZD7442 may offer immediate and long-term protection to people who have been recently exposed to the SARS-CoV-2 and prevent them from developing COVID-19 infection. Two clinical trials are being conducted to test a LAAB combination treatment against COVID-19. AZD7442 is also being tested on people who may not respond to vaccination, like those with compromised immune system.